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Introduction
The use of targeted next-generation sequencing (NGS) in clinical 
genomics has increased the capacity, throughput and afford-
ability of gene testing1–3. Use of NGS data in the clinical setting 
requires comprehensive validation of methods. Ideally, this should 
include evaluation of the NGS test performance in samples with 
pre-determined positive and negative results to provide information 
on sensitivity, specificity and false detection rate.
Deletions and duplications of whole exons, termed ‘exon copy 
number variants’ or ‘exon CNVs’, are an important class of clini-
cally relevant gene mutations4. Accurate exon CNV detection has 
proved difficult in targeted NGS data, particularly if only a single 
exon is affected5. This has led many research and clinical laborato-
ries to either exclude exon CNV detection or to use separate meth-
ods for their detection, which can substantially increase the time 
and cost of tests.
Datasets are available for base substitutions and small insertions 
and deletions6,7 and for copy number variants6, but datasets with 
experimentally validated exon CNV data are not widely available. 
As a result, methods for detecting exon CNVs in NGS data are usu-
ally evaluated using simulated and/or in-house data. This hinders 
tool comparisons, transparency and reproducibility.
We recently released DECoN (www.icr.ac.uk/DECoN), a tool opti-
mised to detect exon CNVs in targeted NGS panels in the clinical 
setting8. During our validation of DECoN performance, we utilised 
samples with orthogonally generated exon CNV data. This proved 
extremely valuable in our evaluations and we believe such data will 
also be highly useful to others. We have therefore put together the 
ICR96 exon CNV validation series, which we present here. This 
was undertaken as part of the Transforming Genetic Medicine Ini-
tiative (TGMI, www.thetgmi.org), a Wellcome funded initiative 
which is developing frameworks and resources to facilitate genetic 
medicine.
The ICR96 exon CNV validation series includes data from 96 sam-
ples. Each sample has sequencing data generated using the TruSight 
Cancer Panel (TSCP) a gene-targeted NGS assay for analysis of 
cancer predisposition genes8–11 and Multiplex Ligation-dependent 
Probe Amplification (MLPA) data12. 66 samples contain at least one 
validated exon CNV, including 25 single exon CNVs and 30 sam-
ples have validated negative results for 26 genes. Of note, the series 
has excellent representation of the cancer predisposition genes most 
frequently tested in clinical practice with 46 exon CNVs in one of 
BRCA1, BRCA2, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM or 
PTEN.
The ICR96 exon CNV validation series has been extremely helpful 
in our assessment of exon CNV detection tools, and the comprehen-
sive orthogonal data allows evaluation of sensitivity, specificity and 
false detection rate. We believe the ICR96 exon CNV validation 
series could serve as a benchmarking set, particularly for the many 
clinical and research laboratories now undertaking cancer predis-
position gene testing.
Materials and methods
The data included in this resource were generated from two types of 
studies. Firstly, through the BOCS, FACT and COG studies, which 
aimed to discover and characterise disease predisposition genes. 
All patients gave informed consent for use of their DNA in genetic 
research. The studies have been approved by the London Multicen-
tre Research Ethics Committee (MREC/01/2/18, MREC/01/2/044, 
05/MRE02/17 respectively). Secondly, the data included here was 
obtained through clinical testing by the TGLclinical laboratory, an 
ISO 15189 accredited genetic testing laboratory that we run. The 
consent given from patients tested through TGLclinical includes, 
as standard, consent for the use of samples for quality-control. It 
also provides the option of consenting to the use of samples/data in 
research; all patients whose data was included in the ICR96 series 
approved this option.
We generated high-quality targeted NGS data for the ICR96 exon 
CNV validation series using the TruSight Cancer Panel (TSCP) 
v2 which targets exons from 100 cancer predisposition genes 
(Supplementary File 1). We prepared targeted DNA libraries from 
50 ng genomic DNA using the TSCP and TruSight Rapid Capture 
kit (Illumina). We followed the manufacturer’s protocol, with the 
exception of library enrichment pool complexity, which we per-
formed in 48-plex. We sequenced a final 10 pM pooled library on 
a HiSeq 2500 platform set in Rapid-run mode following standard 
protocols: 96-plex pool per flow cell, HiSeq® Rapid SBS Kit v2, 
101 bp paired-end dual index run, and onboard clustering using 
HiSeq® Rapid PE Cluster Kit v2. CASAVA v1.8.1 (Illumina) was 
used to demultiplex and create FASTQ files per sample from the 
raw base call files.
All 96 samples also had independently generated exon CNV data 
available. Standard MLPA and/or MLPA by NGS was performed 
for one or more of the following 32 genes: APC, ATM, BAP1, 
BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, 
CDKN2A, CHEK2, EPCAM (exon 9 only), FH, MLH1, MSH2, 
MSH6, MUTYH, NBN, NF1, NSD1, PALB2, PMS2 (excluding 
exons 12-15), PTEN, RAD51C, RAD51D, RB1, SDHB, SMAD4, 
STK11, TP53 and WT1 (Supplementary Table 1). The EZH2 exon 
1-20 deletion was identified by comparative genomic hybridisation 
(CGH) array and was also confirmed by fluorescent in situ hybridi-
sation (FISH). For simplicity, we included this one CGH result with 
the MLPA results.
We provide genomic coordinates in both build 37 and build 38 
for all results (Supplementary Table 1). The genomic coordinates 
are the most 5’ and most 3’ coordinates of the exons involved in 
the exon CNV, as determined by MLPA, according to the speci-
fied transcript. Of note, these are not the actual breakpoints; nei-
ther MLPA nor targeted NGS data can provide breakpoint sequence 
information for exon CNVs. We provide the MLPA results for all 
exon CNVs using the following notation “Exon X deletion/duplica-
tion” for single exon CNVs and “Exon X-Y deletion/duplication” 
for exon CNVs involving more than one exon, where X specifies 
the number of the first exon involved in the exon CNV with respect 
to the transcript, Y specifies the number of the last exon involved 
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in the exon CNV with respect to the transcript, and deletion or 
duplication is specified as appropriate. For all genes except BRCA1 
the numbering is consecutive from the first non-coding exon in the 
transcript. For BRCA1 we use the conventional clinical numbering 
system which does not include exon 4.
Dataset
The ICR96 exon CNV validation series includes samples 
from 96 individuals. 66 samples contain at least one validated 
exon CNV and 30 samples have validated negative results for 
exon CNVs in 26 genes (Supplementary Table 1). Two of the 
66 individuals had an exon CNV in two different genes, such 
that the dataset includes a total of 68 exon CNVs. This includes 
25 single exon CNVs, the most difficult type of exon CNV to 
detect.
The dataset can be used to evaluate the performance of any tool 
that aims to detect exon CNVs in NGS data. It has particular utility 
in validating cancer predisposition gene exon CNV detection. 
The dataset has excellent representation of the cancer predisposi-
tion genes most frequently tested in clinical practice. BRCA1 and 
BRCA2 are particularly well represented, with 15 BRCA1 exon 
CNVs and 10 BRCA2 exon CNVs, of which 11 and four respec-
tively, are single exon CNVs. The 25 BRCA1 and BRCA2 exon 
CNVs include 22 different mutations. We deliberately included, in 
the same pool, two separate samples with a BRCA1 exon 13 dupli-
cation. This small exon duplication is one of the most common 
BRCA1 mutations in the UK13 and hence we wanted to cover the 
clinical scenario of having two different individuals with this muta-
tion in the same sequencing run. To provide further representation 
of the cancer predisposition genes most frequently tested in clini-
cal practice, the dataset includes 21 exon CNVs in MLH1, MSH2, 
MSH6, PMS2, EPCAM, PTEN or TP53. Between the two pools, we 
ensured there was no difference in the representation of exon CNVs 
in any particular gene or in the proportion of samples without an 
exon CNV, to minimise potential batch effects (Table 1).
Table 1. MLPA results for each pool in the ICR96 exon 
CNV validation series.
Pool 1 Pool 2






















Samples with no exon 
CNV
APC, ATM, BAP1, BARD1, 
BMPR1A, BRCA1, BRCA2, 
BRIP1, CDH1, CDK4, CDKN2A, 
CHEK2, EPCAM, MLH1, MSH2, 
MSH6, MUTYH, NBN, PALB2, 
PMS2, PTEN, RAD51C, RAD51D, 
SMAD4, STK11, TP53
15 15
Page 4 of 9
Wellcome Open Research 2017, 2:35 Last updated: 16 JUN 2017
Data availability
We have deposited the FASTQ files for all 96 samples in the 
European Genome-phenome archive (EGA). The accession 
number is EGAS00001002428. Details of how to access the data is 
available at EGA or from www.icr.ac.uk/icr96.
Researchers and authors that use the ICR96 exon CNV validation 
series should reference this paper and should include the following 
acknowledgement: “This study makes use of the ICR96 exon CNV 
validation series data generated by Professor Nazneen Rahman’s 
team at The Institute of Cancer Research, London as part of the 
TGMI”.
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Supplementary Material
Supplementary File 1. TSCP targeted BED file.
Targets of the Illumina TruSight Cancer Panel (TSCP) in BED file format.
Click here to access the data.
Supplementary Table 1. MLPA results for the ICR96 exon CNV validation series.
Column headings:
SampleID – sample ID in the ICR96 exon CNV validation series
ICR96Pool – pool in the ICR96 exon CNV validation series
Gene – HGNC symbol
MLPAResult – the exon CNV result in standard format for clinical reports if an exon CNV was detected, “Normal” = no exon CNV was 
detected
ResultType – “ExonCNV” = an exon CNV was detected, “Normal” = no exon CNV was detected
ExonCNVType – “Deletion” = exon CNV was a deletion, “Duplication” = exon CNV was a duplication, blank = no exon CNV was 
detected
ExonCNVSize – “Single” = exon CNV involving only one exon, “Multi” = exon CNV involving more than one exon, blank = no exon CNV 
was detected
Chromosome – chromosome
5PrimeExon37 – most 5’ genomic coordinate of most 5’ exon in GRCh37
3PrimeExon37 – most 3’ genomic coordinate of most 3’ exon in GRCh37
5PrimeExon38 – most 5’ genomic coordinate of most 5’ exon in GRCh38 converted from 5PrimeExon37 using LiftOver (https://genome.
ucsc.edu/cgi-bin/hgLiftOver)
3PrimeExon38 – most 3’ genomic coordinate of most 3’ exon in GRCh38 converted from 3PrimeExon37 using LiftOver (https://genome.
ucsc.edu/cgi-bin/hgLiftOver)
ENST65 – the ENST ID from Ensembl v65 used for annotation and genomic coordinates
Click here to access the data.
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